WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsNovocure Ltd (NVCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 3011% more annual revenue ($20.98B vs $674.41M). GEHC leads profitability with a 9.1% profit margin vs -25.7%. GEHC earns a higher WallStSmart Score of 57/100 (C).

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

NVCR

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GEHC.

NVCRUndervalued (+81.5%)

Margin of Safety

+81.5%

Fair Value

$56.90

Current Price

$17.16

$39.74 discount

UndervaluedFair: $56.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

NVCR0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

NVCR4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-52.3%2/10

ROE of -52.3% — below average capital efficiency

EPS GrowthGrowth
-6.0%2/10

Earnings declined 6.0%

Free Cash FlowQuality
$-18.67M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bull Case : NVCR

Revenue growth of 12.3% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : NVCR

The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.

Key Dynamics to Monitor

GEHC profiles as a value stock while NVCR is a turnaround play — different risk/reward profiles.

NVCR carries more volatility with a beta of 0.92 — expect wider price swings.

NVCR is growing revenue faster at 12.3% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 29/100). NVCR offers better value entry with a 81.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Novocure Ltd

HEALTHCARE · MEDICAL DEVICES · USA

NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.

Want to dig deeper into these stocks?